Diagnostic role of antibodies to glutamic acid decarboxylase in latent autoimmune diabetes mellitus in adults

Chinese Medical Journal

Volumn 112, Issue 6, 1999, Pages 554-557

  Zhou, Zhiguang ^a   Ouyang, Lingli ^a   Peng, Jian ^a   Yang, Wen ^a   Wang, Jianmin ^a   Zhu, Xuping ^a   Wu, Hanwen ^a   Dyrberg, Thomas ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Adults; Diagnosis; Glutamic acid decarboxylase antibodies; Latent autoimmune diabetes

Indexed keywords

ANTIBODY; GLUTAMATE DECARBOXYLASE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MIDDLE AGED;

EID: 0033140277     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rowley MJ, Mackay IR, Chen QY, et al. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 1992;41:548-551.
2. Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-362.
3. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303.
4. 65). Chin J Diabetes 1997;5:85-88.
5. Pan XR, Yang WY, Xiao JZ, et al. Characteristics and diagnostic points for latent autoimmune diabetes mellitus in adults. Chin J Intern Med 1997;36:159-164.
6. Gottsater A, Lermmark A, Landin-Olsson M, et al. β-cell function in relation to islet cell antibodies during the first 3 yr after the clinical diagnosis of diabetes in non-insulin-dependent (type II) diabetic patients. Diabetes Care 1993;16:902-910.
7. Niskanen L, Tuomi T, Karjalainen J, et al. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18:1557-1565.
8. Park Y, Zimmet PZ, Lee H, et al. The low prevalence of immunogenetic markers in Korean adult-onset IDDM patients. Diabetes Care 1996;19:241-245.
9. Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995;38:816-822.
10. Kobayashi T, Nakanishi K, Murase T, et al. Small doses of subcutaneous insulin as a strategy for preventing slowy progressive β-cel failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45:622-626.
11. Filippo GD, Carel JC, Biotard C, et al. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 1996; 45: 101-104.